ENDRA Life Sciences Inc. - Form 8-K Summary
Business Context and Reporting Period
Company: ENDRA Life Sciences Inc.
Filing Date: July 26, 2019 (Report Date)
Event: Entry into a Material Definitive Agreement and Unregistered Sales of Equity Securities.
Context: The Company, an emerging growth company, completed a private placement offering to raise capital through the sale of senior secured convertible promissory notes and warrants.
Key Financial Metrics and Transaction Details
- Gross Proceeds: Approximately $2.8 million.
- Principal Amount of Notes: $2,587,895.
- Interest Rate: 10% per annum (increases to 18% upon an event of default).
- Maturity Date: April 26, 2020.
- Conversion Price: $1.49 per share.
- Shares Issuable upon Conversion: 1,736,843 shares of Common Stock.
- Warrant Exercise Price: $1.49 per share.
- Warrant Expiration: July 26, 2022.
- Placement Agent Compensation: 10% commission of gross proceeds, $30,000 expense reimbursement, and a warrant for 173,685 shares.
Material Changes and Agreements
The filing details the execution of several material agreements on July 26, 2019:
- Securities Purchase Agreement: Governs the sale of Notes and Warrants to accredited investors.
- Security Agreement: The Notes are secured by a first-priority lien on substantially all of the Company's assets.
- Registration Rights Agreement: The Company agreed to file a registration statement within 30 days of closing to cover the resale of shares issuable upon conversion or exercise. Failure to file triggers a penalty of 1.0% of the invested amount per 30-day period.
Outlook, Risks, and Contingencies
- Liquidity Impact: The transaction provides immediate liquidity of approximately $2.8 million to fund operations.
- Dilution Risk: The transaction introduces potential dilution through the conversion of notes and exercise of warrants (totaling approximately 1.91 million shares including the placement agent warrant).
- Default Risk: In the event of a default, the interest rate accelerates to 18%, and the principal becomes immediately due and payable.
- Regulatory Compliance: The securities were sold under Section 4(a)(2) and Rule 506(b) exemptions; they are not registered and cannot be resold without registration or an applicable exemption.
Key Facts for Investor Verification
- Verify the Company's ability to service the 10% interest payments due quarterly and the principal repayment in April 2020.
- Confirm the filing of the required Registration Statement within 30 days of July 26, 2019, to avoid penalty payments.
- Assess the impact of the first-priority lien on substantially all assets on future financing capabilities.
- Monitor the Company's cash burn rate relative to the $2.8 million raised to determine runway before the maturity date.